{
  "ticker": "OCC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967666",
  "id": "02967666",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250709",
  "time": "0900",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmlq96pm723l.pdf",
  "summary": "### **Orthocell Limited \u2013 Quarterly Report (June 2025) \u2013 Material Summary**  \n\n#### **Financial Highlights**  \n- **Revenue**:  \n  - Quarterly: **$2.73m** (up 22.8% QoQ, 45.1% YoY)  \n  - FY2025: **$9.19m** (up 35.8% YoY) \u2013 fifth consecutive quarterly record.  \n  - Compound Quarterly Growth Rate (CQGR): **9.5%** over 3 years.  \n- **Cash Position**: **$28.6m** (no debt), up 38.8% YoY.  \n\n#### **Key Operational Developments**  \n1. **Remplir\u2122 (Nerve Repair Product)**:  \n   - **FDA 510(k) clearance** (April 2025); initial US rollout underway.  \n   - First US surgical use completed; distributor network established (14 distributors across 25 states).  \n   - Additional approvals in **Hong Kong, Thailand, Canada**.  \n   - US market potential: **$1.6bn**.  \n\n2. **Striate+\u2122 (Dental Membrane)**:  \n   - Regulatory approval in **Brazil** (annual market opportunity: **$65m**).  \n   - Global distribution via **BioHorizons**; launches planned in Germany/Austria/Switzerland.  \n\n#### **Cash Flow & Liquidity**  \n- **Net operating outflow**: **$3.54m** (quarter), **$8.51m** (FY2025).  \n- **Funding runway**: **8.09 quarters** based on current cash reserves.  \n\n#### **Upcoming Catalyst**  \n- **Expected US sales ramp for Remplir** in 1H FY26.  \n\n**No material capital raises or structural changes disclosed.**",
  "usage": {
    "prompt_tokens": 7618,
    "completion_tokens": 385,
    "total_tokens": 8003,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:11:01.632098"
}